German pharma giant Bayer is uniting with researchers at Johns Hopkins University to ferret out new treatments for retinal diseases, signing a 5-year deal targeting early-stage R&D.
Under the agreement, Bayer will work alongside the school’s Wilmer Eye Institute to spot new therapeutic targets, shed light on disease mechanisms and develop new drug delivery methods for back-of-the-eye ailments. Bayer will have exclusive rights to option any and all drug candidates that emerge from the collaboration, and the companies are keeping quiet on financial details.
{iframe}http://www.fiercebiotech.com/story/bayer-bets-johns-hopkins-eye-disease-rd/2015-06-16{/iframe}